



Metastatic Melanoma: From Gene Profiling to Targeted Therapy

Guest Editors:

Dr. Lluçia Alos

Pathology Department, Hospital
Clinic, Universidad de Barcelona,
08036 Barcelona, Spain

Dr. Cristina Teixidó

Translational Genomic and
Targeted Therapeutics in Solid
Tumors, August Pi i Sunyer
Biomedical Research Institute
(IDIBAPS), 08036 Barcelona,
Spain

Deadline for manuscript
submissions:

15 June 2024

Message from the Guest Editors

Dear Colleagues,

The development and progression of melanoma is a consequence of an uncontrolled cell growth due to a combination of genetic alterations that lead to neoplastic transformation and the escape from inhibitory signals. In addition to the genetic alterations of tumor cells that lead to cell proliferation, a regulatory role has been attributed to the tumor microenvironment (TME), which in turn is regulated by the gene profile. The TME interacts with the host's immune system and plays important roles in tumor progression, immune escape, and metastasis. The progressive understanding of melanoma molecular pathways and TME regulation has enabled the development of successful targeted therapies and immunotherapies for unresectable stage III and IV melanoma. An increased understanding of the role of genes and proteins in key signaling pathways in melanoma progression is needed for more effective treatments.

This Special Issue will highlight the role of genetic alterations in melanoma cells and TME regulation, covering both basic and translational aspects that advance our understanding in order to find therapies for melanoma.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI